
FDA Approves Multi-Dose Vial of Thiotepa for Breast and Ovarian Cancer
The FDA has approved a ready-to-dilute formulation of thiotepa (Tepylute) in a 100-mg/10-mL multi-dose vial for the treatment of patients with breast and ovarian cancer.1 Thiotepa, which was originally approved by the FDA in 1959, is an alkylating drug …